Progressive Supranuclear Palsy Treatment

PUBLISHED: August 16, 2024

PAGES: 134 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Progressive Supranuclear Palsy Treatment Market to Reach US$19.1 Million by 2030

The global market for Progressive Supranuclear Palsy Treatment estimated at US$13.6 Million in the year 2023, is expected to reach US$19.1 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Pharmacological Therapy, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$8.7 Million by the end of the analysis period. Growth in the Physical Therapy segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Million While China is Forecast to Grow at 4.7% CAGR

The Progressive Supranuclear Palsy Treatment market in the U.S. is estimated at US$3.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Key Trends and Drivers

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder that affects movement, control of walking (gait) and balance, speech, swallowing, vision, mood and behavior, and cognitive abilities. It arises due to the deterioration of brain cells in specific areas of the brain, primarily those that control the body's movements and cognitive functions. The most distinctive symptom, which often results in early misdiagnosis, involves a loss of balance while walking and difficulty managing eye movements, specifically in looking up and down. These symptoms progressively worsen, often leading to life-threatening complications such as pneumonia, due to swallowing difficulties. Currently, there is no cure for PSP, and treatments focus on managing symptoms to improve quality of life. This management can involve medication to reduce symptoms, physical therapy to enhance mobility and prevent falls, and speech therapy to address communication challenges.

Research and development within the field of PSP treatment are ongoing, with several innovative approaches under investigation. Pharmacological research primarily focuses on neuroprotective and disease-modifying drugs that aim to slow the progression of the disease or alleviate its symptoms. Most promising among these are tau protein aggregation inhibitors, as abnormal accumulation of tau is a hallmark of PSP. Non-pharmacological interventions are also being explored, such as deep brain stimulation and other neurosurgical options, though these are still in the early stages of research. Given the complexity of PSP symptoms, multidisciplinary care approaches are increasingly adopted, involving neurologists, physical therapists, speech therapists, and occupational therapists, designed to address the broad spectrum of symptoms experienced by patients.

The growth in the Progressive Supranuclear Palsy market is driven by several factors, including the increasing prevalence of neurodegenerative disorders with aging populations globally, which heightens the demand for more effective treatments. Advances in diagnostic technologies have also significantly contributed, allowing for earlier and more accurate diagnosis of PSP, thereby increasing the number of individuals eligible for treatment. Another key driver is the rising investment in research and development by biotech and pharmaceutical companies aimed at finding a cure or more effective management options for PSP. Enhanced awareness and advocacy for rare disorders have also fostered a supportive regulatory environment that often includes incentives like tax breaks, funding grants, and fast-track approvals for novel therapies. Furthermore, growing patient advocacy movements are emphasizing the need for tailored healthcare solutions, influencing both market demand and the focus of ongoing clinical research. These factors collectively stimulate advancements in treatment approaches and the development of the PSP market, promising improved patient outcomes and expanded therapeutic possibilities.

Select Competitors (Total 86 Featured) -

AbbVie, Inc.
AC Immune SA
Alzprotect
Amylyx Pharmaceuticals
Asahi Kasei Pharma Corporation
Asceneuron
Biogen, Inc.
Grupo Ferrer Internacional, S.A.
Oncolys BioPharma
Retrotope
TauRx Pharmaceuticals Ltd.
Transposon Therapeutics, Inc.
UCB SA
Woolsey Pharmaceuticals

Product Code: MCP26820

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Progressive Supranuclear Palsy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Growing Awareness and Diagnosis Rates of Progressive Supranuclear Palsy
- Advances in Neuroimaging Technologies Enhancing Diagnostic Accuracy
- Emerging Biomarkers for Early and Accurate Diagnosis
- Development of Disease-Modifying Therapies
- Impact of Genetic Research on Treatment Approaches
- Increased Funding for Rare Neurodegenerative Disorders
- Government Initiatives Supporting Neurological Research
- Expansion of Targeted Therapy and Personalized Medicine
- Innovations in Drug Delivery Systems
- Integration of AI and Machine Learning in Drug Development
- Challenges in Clinical Trial Recruitment
- Global Health Aging Populations Increasing Prevalence
- Neuroprotective Treatment Approaches Gaining Traction
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Progressive Supranuclear Palsy Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Progressive Supranuclear Palsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Pharmacological Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Pharmacological Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Physical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Speech Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Speech Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Speech Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Symptomatic Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Symptomatic Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Symptomatic Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 19: USA 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 22: Canada 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
JAPAN
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 25: Japan 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
CHINA
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 27: China Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 28: China 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
EUROPE
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Progressive Supranuclear Palsy Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 34: Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
FRANCE
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 36: France Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 37: France 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
GERMANY
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 40: Germany 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 43: Italy 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 46: UK 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Progressive Supranuclear Palsy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030
REST OF WORLD
- TABLE 53: Rest of World Recent Past, Current & Future Analysis for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
- TABLE 54: Rest of World Historic Review for Progressive Supranuclear Palsy Treatment by Treatment Type - Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
- TABLE 55: Rest of World 16-Year Perspective for Progressive Supranuclear Palsy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Pharmacological Therapy, Physical Therapy, Speech Therapy and Symptomatic Management for the Years 2014, 2024 & 2030